HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

William R Roeske Selected Research

Pain (Aches)

6/2012Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.
3/2012Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.
12/2010Sustained morphine treatment augments prostaglandin E2-evoked calcitonin gene-related peptide release from primary sensory neurons in a PKA-dependent manner.
9/2009Sustained morphine treatment augments capsaicin-evoked calcitonin gene-related peptide release from primary sensory neurons in a protein kinase A- and Raf-1-dependent manner.
5/2009Sustained cannabinoid agonist treatment augments CGRP release in a PKA-dependent manner.
12/2008Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.
4/2008Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner.
12/2003Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


William R Roeske Research Topics

Disease

8Pain (Aches)
06/2012 - 12/2003
6Hyperalgesia
06/2012 - 12/2008
1Ischemia
07/2007
1Myocardial Infarction
07/2007
1Infarction (Infarctions)
07/2007
1Myocardial Ischemia (Ischemic Heart Diseases)
07/2007
1Chronic Pain
07/2006
1Tics (Tic)
02/2003

Drug/Important Bio-Agent (IBA)

7Opioid Analgesics (Opioids)IBA
06/2012 - 12/2003
6Morphine (MS Contin)FDA LinkGeneric
06/2012 - 07/2006
6Neurotransmitter Agents (Neurotransmitter)IBA
12/2010 - 12/2003
5Calcitonin Gene-Related PeptideIBA
12/2010 - 04/2008
2Analgesics (Analgesic Drugs)IBA
04/2008 - 07/2006
2delta Opioid Receptors (delta Opioid Receptor)IBA
07/2007 - 02/2003
1Tryptophan (L-Tryptophan)FDA Link
06/2012
1Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA
06/2012
1TachykininsIBA
06/2012
1Pharmaceutical PreparationsIBA
06/2012
1AM 1241IBA
03/2012
1Cannabinoid Receptors (Cannabinoid Receptor)IBA
03/2012
1Cyclic AMP (AMP, Cyclic)IBA
12/2010
1ProstaglandinsIBA
12/2010
1Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA
12/2010
1Capsaicin (Zostrix)FDA Link
09/2009
1CannabinoidsIBA
05/2009
1Small Interfering RNA (siRNA)IBA
12/2008
15- iodo- 3- ((3,5- dibromo- 4- hydroxyphenyl)methylene)- 2- indolinoneIBA
04/2008
1Epinephrine (Adrenaline)FDA LinkGeneric
07/2007
1D-Penicillamine (2,5)- EnkephalinIBA
07/2007
1Opioid Peptides (Opioid Peptide)IBA
02/2003
1AcidsIBA
02/2003
1methyl- 2',6'- dimethyltyrosinyltetrahydroisoquinoline- 3- carboxylic acidIBA
02/2003
1hydroxide ionIBA
02/2003

Therapy/Procedure

1Analgesia
12/2003